David A. Siegel Nuvation Bio Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 871,500 shares of NUVB stock, worth $4.24 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
871,500
Previous 454,900
91.58%
Holding current value
$4.24 Million
Previous $887,000
263.47%
% of portfolio
0.01%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding NUVB
# of Institutions
217Shares Held
165MCall Options Held
1.99MPut Options Held
660K-
Decheng Capital LLC Menlo Park, CA26MShares$126 Million16.75% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$78.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$75.1 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY9.71MShares$47.2 Million0.67% of portfolio
-
Omega Fund Management, LLC Boston, MA8.83MShares$42.9 Million89.01% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $1.06B
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...